Abstract
The C-X-C chemokine receptor-4(CXCR4) is a G-protein coupled receptor (GPCR) which belongs to the family I GPCR or rhodopin-like GPCR family. CXCR4 plays a crucial role as a co-receptor with CCR5 for HIV-1 anchoring to mammalian cell membrane, and is implicated in cancer metastasis and inflammation. Recently, crystal structure of human CXCR4 receptor was reported, which facilitates the structure-based drug discovery of CXCR4 significantly. Here we summarize the structure feature of C-X-C chemokine and its difference from other rhodopsin-like GPCR family, the impact of recent crystal structure on CXCR4 drug development, the available active compounds for CXCR4 receptor, SAR studies of the available active compounds, the recognition mechanism of the inhibitors of CXCR4 receptor (molecular docking results and molecular dynamics results), which illustrates the interaction between the inhibitors and critical residues of CXCR4, and the outlook of drug development for CXCR4 receptor.
Keywords: CXCR4, crystal structure, anti-HIV-1 inhibitors, DOCK, molecular dynamics, SAR, drug development, critical residues, chemokine receptor, antagonist
Current Computer-Aided Drug Design
Title:Structure-Based Development of Antagonists for Chemokine Receptor CXCR4
Volume: 9 Issue: 1
Author(s): Chongqian Zhang, Tingjun Hou, Zhiwei Feng and Youyong Li
Affiliation:
Keywords: CXCR4, crystal structure, anti-HIV-1 inhibitors, DOCK, molecular dynamics, SAR, drug development, critical residues, chemokine receptor, antagonist
Abstract: The C-X-C chemokine receptor-4(CXCR4) is a G-protein coupled receptor (GPCR) which belongs to the family I GPCR or rhodopin-like GPCR family. CXCR4 plays a crucial role as a co-receptor with CCR5 for HIV-1 anchoring to mammalian cell membrane, and is implicated in cancer metastasis and inflammation. Recently, crystal structure of human CXCR4 receptor was reported, which facilitates the structure-based drug discovery of CXCR4 significantly. Here we summarize the structure feature of C-X-C chemokine and its difference from other rhodopsin-like GPCR family, the impact of recent crystal structure on CXCR4 drug development, the available active compounds for CXCR4 receptor, SAR studies of the available active compounds, the recognition mechanism of the inhibitors of CXCR4 receptor (molecular docking results and molecular dynamics results), which illustrates the interaction between the inhibitors and critical residues of CXCR4, and the outlook of drug development for CXCR4 receptor.
Export Options
About this article
Cite this article as:
Zhang Chongqian, Hou Tingjun, Feng Zhiwei and Li Youyong, Structure-Based Development of Antagonists for Chemokine Receptor CXCR4, Current Computer-Aided Drug Design 2013; 9 (1) . https://dx.doi.org/10.2174/1573409911309010006
DOI https://dx.doi.org/10.2174/1573409911309010006 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Liver Transporters in Hepatic Drug Disposition: An Update
Current Drug Metabolism Genetic Variants of Drug Metabolizing Enzymes and Drug Transporter (ABCB1) as Possible Biomarkers for Adverse Drug Reactions in an HIV/AIDS Cohort in Zimbabwe
Current HIV Research Statins, Mevalonate Pathway and its Intermediate Products in Placental Development and Preeclampsia
Current Molecular Pharmacology Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) New Ways to Improve Breast Cancer Therapy Targeting Specific Molecular Pathways
Current Cancer Therapy Reviews Interventions to Reduce Cardiovascular Risk in Children with Type 1 Diabetes
Current Diabetes Reviews From Alpha to Omega with Aβ: Targeting the Multiple Molecular Appearances of the Pathogenic Peptide in Alzheimers Disease
Current Medicinal Chemistry Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Procyanidins and Their Healthy Protective Effects Against Type 2 Diabetes
Current Medicinal Chemistry The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Current Neuropharmacology Selective Modulation of Aβ42 Production in Alzheimers Disease: Non-Steroidal Anti-Inflammatory Drugs and Beyond
Current Pharmaceutical Design Monoclonal Antibodies in the Treatment of Leukemia
Current Molecular Medicine Probiotics for the Prevention and Treatment of Allergies, with an Emphasis on Mode of Delivery and Mechanism of Action
Current Pharmaceutical Design Recent Patents on Nucleic Acid-Based Antiviral Therapeutics
Recent Patents on Anti-Infective Drug Discovery Inhaled Biologics: From Preclinical to Product Approval
Current Pharmaceutical Design A QSAR Study of HIV Protease Inhibitors Using Theoretical Descriptors
Current Computer-Aided Drug Design Peptide Therapeutics in Neurodegenerative Disorders
Current Medicinal Chemistry Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets Cardiovascular Physiology of Androgens and Androgen Testosterone Therapy in Postmenopausal Women
Endocrine, Metabolic & Immune Disorders - Drug Targets